Sales Nexus CRM

Vycor Medical Reports Revenue Decline but Highlights Growing Clinical Evidence for VBAS

By FisherVista•
Vycor Medical's revenue fell 19% in Q3 2026 due to tough comparisons, but the company remains operationally profitable and continues to build clinical support for its ViewSite Brain Access System.
Vycor Medical Reports Revenue Decline but Highlights Growing Clinical Evidence for VBAS

Vycor Medical, Inc. (OTCQB: VYCO) on November 13, 2026 reported financial results for the three and nine months ended September 30, 2026, showing a decline in revenue but continued operating profitability and expanding clinical validation for its flagship neurosurgical device. The Boca Raton, Florida-based company operates through two business units: Vycor Medical, which produces the ViewSite Brain Access System (VBAS) for neurosurgeons, and NovaVision, a business in development offering therapy programs for patients recovering from visual disorders after stroke or other brain injury.

For the third quarter, total revenue was $414,895, a 19% decrease from the prior-year period. The Vycor Medical division generated $402,048 in revenue, down 18% from $492,102 in 2025. The company attributed the decline largely to higher-than-normal U.S. sales in the 2025 period, when it added new hospitals and received bulk orders from some existing hospitals. International sales increased for the three-month period but decreased slightly over the nine months, which the company noted can be lumpy as large orders sometimes fall in different quarters. For the nine months ended September 30, 2026, total revenue was $1,291,699, an 11% decrease from the prior year, with the Vycor Medical division contributing $1,243,713, down 11%.

Despite the revenue decline, Vycor remained operationally profitable. GAAP operating profit was $27,424 for the third quarter compared to $32,085 in 2025, and $80,083 for the nine months compared to $70,425 in the prior-year period. Non-GAAP operating profit, which excludes non-cash depreciation and stock-based compensation, was $43,011 for the quarter versus $60,162 in 2025, and $125,751 for the nine months versus $166,262. Gross profit for the quarter was $353,017, a 22% decrease, yielding a margin of 85% compared to 88% in the prior year. The NovaVision division, still in development, generated $12,847 in third-quarter revenue, a 41% increase over 2025, and $47,986 for the nine months, an 11% increase.

During 2026 to date, four new peer-reviewed studies were published on VBAS, bringing the total number of published peer-reviewed clinical papers to 54, with an additional 14 other clinical papers. One study was a case study on a complex pediatric tumor that highlighted the effectiveness of integrating neuro-navigation systems with VBAS as “a paramount strategy for the surgical resection” of such lesions. Another was a retrospective study of 23 patients comparing tumor resection outcomes using VBAS with traditional blade retractors, finding significantly fewer new neurological deficits in the tubular retractor group, implying safer tumor resection. A third paper reported on a single-center study of 29 adults undergoing minimally invasive suboccipital tubular resection of posterior fossa metastases, concluding that the technique enables effective decompression with low cerebrospinal fluid diversion rates. The most recent paper described two cases of intracerebral hemorrhage evacuation in Japan using VBAS with an exoscope, highlighting how the device provided a stable corridor with sufficient visualization and working space for deep hemostasis using familiar microsurgical instruments.

The company noted that VBAS is FDA-cleared and has been used in over 350 hospitals in the U.S. and numerous countries internationally, protected by 49 issued and 8 pending patents. For an overview of the device, the company offers a VBAS Video, and more information is available at www.vycormedical.com and www.vycorvbas.com. NovaVision provides clinically supported vision rehabilitation therapies, including Visual Restoration Therapy, the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage. A NovaVision Video offers an overview, and additional details are available at www.novavision.com. The full financial results were announced through NEWMEDIAWIRE, and the original release can be viewed at www.newmediawire.com.

FisherVista

FisherVista

@fishervista